Abstract
Several cellular signaling pathways are regulated by ADP-ribosylation, a posttranslational modification catalyzed by members of the ARTD superfamily. Tankyrases are distinguishable from the rest of this family by their unique domain organization, notably the sterile alpha motif responsible for oligomerization and ankyrin repeats mediating protein-protein interactions. Tankyrases are involved in various cellular functions, such as telomere homeostasis, Wnt/β-catenin signaling, glucose metabolism, and cell cycle progression. In these processes, Tankyrases regulate the interactions and stability of target proteins by poly (ADP-ribosyl)ation. Modified proteins are subsequently recognized by the E3 ubiquitin ligase RNF146, poly-ubiquitinated and predominantly guided to 26S proteasomal degradation. Several small molecule inhibitors have been described for Tankyrases; they compete with the co-substrate NAD+ for binding to the ARTD catalytic domain. The recent, highly potent and selective inhibitors possess several properties of lead compounds and can be used for proof-of-concept studies in cancer and other Tankyrase linked diseases.
Keywords: Cancer, drug design, enzyme, inhibitor, tankyrase, telomere, Wnt/β-catenin signaling.
Current Pharmaceutical Design
Title:Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Volume: 20 Issue: 41
Author(s): Teemu Haikarainen, Stefan Krauss and Lari Lehtio
Affiliation:
Keywords: Cancer, drug design, enzyme, inhibitor, tankyrase, telomere, Wnt/β-catenin signaling.
Abstract: Several cellular signaling pathways are regulated by ADP-ribosylation, a posttranslational modification catalyzed by members of the ARTD superfamily. Tankyrases are distinguishable from the rest of this family by their unique domain organization, notably the sterile alpha motif responsible for oligomerization and ankyrin repeats mediating protein-protein interactions. Tankyrases are involved in various cellular functions, such as telomere homeostasis, Wnt/β-catenin signaling, glucose metabolism, and cell cycle progression. In these processes, Tankyrases regulate the interactions and stability of target proteins by poly (ADP-ribosyl)ation. Modified proteins are subsequently recognized by the E3 ubiquitin ligase RNF146, poly-ubiquitinated and predominantly guided to 26S proteasomal degradation. Several small molecule inhibitors have been described for Tankyrases; they compete with the co-substrate NAD+ for binding to the ARTD catalytic domain. The recent, highly potent and selective inhibitors possess several properties of lead compounds and can be used for proof-of-concept studies in cancer and other Tankyrase linked diseases.
Export Options
About this article
Cite this article as:
Haikarainen Teemu, Krauss Stefan and Lehtio Lari, Tankyrases: Structure, Function and Therapeutic Implications in Cancer, Current Pharmaceutical Design 2014; 20 (41) . https://dx.doi.org/10.2174/1381612820666140630101525
DOI https://dx.doi.org/10.2174/1381612820666140630101525 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry FOXM1 and its Oncogenic Signaling in Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery Biologically Active Selenophenes and Benzo[b]selenophenes
Current Organic Synthesis Astrocytes as a 5-HT2B-Mediated SERT-Independent SSRI Target, Slowly Altering Depression-Associated Genes and Function
Current Signal Transduction Therapy Predictive Biomarkers and Novel Targets in the Treatment of Metastatic Renal Cell Carcinoma
Current Medicinal Chemistry Beneficial Extracardiac Effects of Cardiovascular Medications
Current Cardiology Reviews Molecular Pathogenesis of Non Muscle-Invasive Bladder Cancer: Implications for Novel Targeted Therapies
Current Molecular Medicine The Re-Emergence of Aerosol Gene Delivery: A Viable Approach to Lung Cancer Therapy
Current Cancer Drug Targets Oxidative DNA Damage and Oxidant/Anti-Oxidant Enzymatic Systems in Carcinogenesis and Cancer Progression
Current Enzyme Inhibition Subtype-Selective Dopamine Receptor Radioligands for PET Imaging: Current Status and Recent Developments
Current Medicinal Chemistry Management of the Menopausal Disturbances and Oxidative Stress
Current Pharmaceutical Design Identification of a RhoA- and SRF-Dependent Mechanism of Androgen Action that is Associated with Prostate Cancer Progression
Current Drug Targets Machine Learning and Perturbation Theory Machine Learning (PTML) in Medicinal Chemistry, Biotechnology, and Nanotechnology
Current Topics in Medicinal Chemistry Inhibition of EGFR Signaling by N-cyclohexyl-2-(1-(phenylsulfonyl)piperidin-4-yl) acetamide
Anti-Cancer Agents in Medicinal Chemistry Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets Preclinical Investigation of Radiopharmaceuticals: An Accurate and Multidisciplinary Approach
Current Radiopharmaceuticals Cancer Cell Cannibalism: A Primeval Option to Survive.
Current Molecular Medicine Novel Concepts in the Development of Platinum Antitumor Drugs
Current Medicinal Chemistry - Anti-Cancer Agents The Canalicular Bile Salt Export Pump BSEP (ABCB11) as a Potential Therapeutic Target
Current Drug Targets Activation of LINE-1 Retrotransposon Increases the Risk of Epithelial-Mesenchymal Transition and Metastasis in Epithelial Cancer
Current Molecular Medicine